"Rhabdomyosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
| Descriptor ID |
D012208
|
| MeSH Number(s) |
C04.557.450.590.550.660 C04.557.450.795.550.660
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rhabdomyosarcoma".
Below are MeSH descriptors whose meaning is more specific than "Rhabdomyosarcoma".
This graph shows the total number of publications written about "Rhabdomyosarcoma" by people in this website by year, and whether "Rhabdomyosarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 2 | 3 |
| 2003 | 2 | 0 | 2 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 4 | 2 | 6 |
| 2011 | 2 | 0 | 2 |
| 2013 | 3 | 1 | 4 |
| 2014 | 5 | 0 | 5 |
| 2015 | 3 | 0 | 3 |
| 2016 | 2 | 1 | 3 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 3 | 1 | 4 |
| 2020 | 5 | 0 | 5 |
| 2021 | 7 | 0 | 7 |
| 2022 | 10 | 0 | 10 |
| 2023 | 13 | 0 | 13 |
| 2024 | 12 | 0 | 12 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rhabdomyosarcoma" by people in Profiles.
-
Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers. JCO Precis Oncol. 2025 Feb; 9:e2400556.
-
miR-449a/miR-340 reprogram cell identity and metabolism in fusion-negative rhabdomyosarcoma. Cell Rep. 2025 Jan 28; 44(1):115171.
-
Salvage Therapy Efficacy is Modified by Risk Group at Diagnosis in Patients With Relapsed Rhabdomyosarcoma. Pediatr Blood Cancer. 2025 Mar; 72(3):e31477.
-
Implications of Implementing Children's Oncology Group Risk Stratification to Patients With Rhabdomyosarcoma Treated on European Paediatric Soft Tissue Sarcoma Study Group Clinical Trial. Pediatr Blood Cancer. 2025 Feb; 72(2):e31436.
-
Late Events Occurring After 5?Years in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2025 Jan; 72(1):e31421.
-
Whole Lung Irradiation in Rhabdomyosarcoma With Lung Metastases: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2024 Dec 20; 42(36):4263-4270.
-
Outcomes for patients with perineal and perianal rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Pediatr Blood Cancer. 2024 Nov; 71(11):e31303.
-
Children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone treated on Children's Oncology Group studies. Pediatr Blood Cancer. 2024 Oct; 71(10):e31200.
-
Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. Lancet Oncol. 2024 Jul; 25(7):912-921.
-
Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials. Cancer. 2024 Nov 15; 130(22):3785-3796.